225 related articles for article (PubMed ID: 33339338)
1. How to Separate Kinase Inhibition from Undesired Monoamine Oxidase A Inhibition-The Development of the DYRK1A Inhibitor AnnH75 from the Alkaloid Harmine.
Wurzlbauer A; Rüben K; Gürdal E; Chaikuad A; Knapp S; Sippl W; Becker W; Bracher F
Molecules; 2020 Dec; 25(24):. PubMed ID: 33339338
[TBL] [Abstract][Full Text] [Related]
2. Structure-Based Design and Synthesis of Harmine Derivatives with Different Selectivity Profiles in Kinase versus Monoamine Oxidase Inhibition.
Bálint B; Wéber C; Cruzalegui F; Burbridge M; Kotschy A
ChemMedChem; 2017 Jun; 12(12):932-939. PubMed ID: 28264138
[TBL] [Abstract][Full Text] [Related]
3. Identification of harmine and β-carboline analogs from a high-throughput screen of an approved drug collection; profiling as differential inhibitors of DYRK1A and monoamine oxidase A and for in vitro and in vivo anti-cancer studies.
Tarpley M; Oladapo HO; Strepay D; Caligan TB; Chdid L; Shehata H; Roques JR; Thomas R; Laudeman CP; Onyenwoke RU; Darr DB; Williams KP
Eur J Pharm Sci; 2021 Jul; 162():105821. PubMed ID: 33781856
[TBL] [Abstract][Full Text] [Related]
4. Selectivity Profiling and Biological Activity of Novel β-Carbolines as Potent and Selective DYRK1 Kinase Inhibitors.
Rüben K; Wurzlbauer A; Walte A; Sippl W; Bracher F; Becker W
PLoS One; 2015; 10(7):e0132453. PubMed ID: 26192590
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
Liu W; Liu X; Tian L; Gao Y; Liu W; Chen H; Jiang X; Xu Z; Ding H; Zhao Q
Eur J Med Chem; 2021 Oct; 222():113554. PubMed ID: 34098466
[TBL] [Abstract][Full Text] [Related]
6. Exploiting the repertoire of CK2 inhibitors to target DYRK and PIM kinases.
Cozza G; Sarno S; Ruzzene M; Girardi C; Orzeszko A; Kazimierczuk Z; Zagotto G; Bonaiuto E; Di Paolo ML; Pinna LA
Biochim Biophys Acta; 2013 Jul; 1834(7):1402-9. PubMed ID: 23360763
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of β-carboline derivatives as potential monoamine oxidase inhibitors.
Reniers J; Robert S; Frederick R; Masereel B; Vincent S; Wouters J
Bioorg Med Chem; 2011 Jan; 19(1):134-44. PubMed ID: 21183355
[TBL] [Abstract][Full Text] [Related]
8. Harmine is an ATP-competitive inhibitor for dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A).
Adayev T; Wegiel J; Hwang YW
Arch Biochem Biophys; 2011 Mar; 507(2):212-8. PubMed ID: 21185805
[TBL] [Abstract][Full Text] [Related]
9. Isoform selectivity of harmine-conjugated 1,2,3-triazoles against human monoamine oxidase.
Haider S; Alhusban M; Chaurasiya ND; Tekwani BL; Chittiboyina AG; Khan IA
Future Med Chem; 2018 Jun; 10(12):1435-1448. PubMed ID: 29788780
[TBL] [Abstract][Full Text] [Related]
10. Computational & experimental evaluation of the structure/activity relationship of β-carbolines as DYRK1A inhibitors.
Drung B; Scholz C; Barbosa VA; Nazari A; Sarragiotto MH; Schmidt B
Bioorg Med Chem Lett; 2014 Oct; 24(20):4854-60. PubMed ID: 25240617
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and Biological Validation of a Harmine-Based, Central Nervous System (CNS)-Avoidant, Selective, Human β-Cell Regenerative Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase A (DYRK1A) Inhibitor.
Kumar K; Wang P; Wilson J; Zlatanic V; Berrouet C; Khamrui S; Secor C; Swartz EA; Lazarus M; Sanchez R; Stewart AF; Garcia-Ocana A; DeVita RJ
J Med Chem; 2020 Mar; 63(6):2986-3003. PubMed ID: 32003560
[TBL] [Abstract][Full Text] [Related]
12. Development of Kinase-Selective, Harmine-Based DYRK1A Inhibitors that Induce Pancreatic Human β-Cell Proliferation.
Kumar K; Wang P; Sanchez R; Swartz EA; Stewart AF; DeVita RJ
J Med Chem; 2018 Sep; 61(17):7687-7699. PubMed ID: 30059217
[TBL] [Abstract][Full Text] [Related]
13. Rational Design and Identification of Harmine-Inspired, N-Heterocyclic DYRK1A Inhibitors Employing a Functional Genomic In Vivo Drosophila Model System.
Huizar FJ; Hill HM; Bacher EP; Eckert KE; Gulotty EM; Rodriguez KX; Tucker ZD; Banerjee M; Liu H; Wiest O; Zartman J; Ashfeld BL
ChemMedChem; 2022 Feb; 17(4):e202100512. PubMed ID: 34994084
[TBL] [Abstract][Full Text] [Related]
14. Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation.
Göckler N; Jofre G; Papadopoulos C; Soppa U; Tejedor FJ; Becker W
FEBS J; 2009 Nov; 276(21):6324-37. PubMed ID: 19796173
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of a series of unsaturated ketone derivatives as selective and reversible monoamine oxidase inhibitors.
Choi JW; Jang BK; Cho NC; Park JH; Yeon SK; Ju EJ; Lee YS; Han G; Pae AN; Kim DJ; Park KD
Bioorg Med Chem; 2015 Oct; 23(19):6486-96. PubMed ID: 26337020
[TBL] [Abstract][Full Text] [Related]
16. Activation, regulation, and inhibition of DYRK1A.
Becker W; Sippl W
FEBS J; 2011 Jan; 278(2):246-56. PubMed ID: 21126318
[TBL] [Abstract][Full Text] [Related]
17. beta-Carboline alkaloids in Peganum harmala and inhibition of human monoamine oxidase (MAO).
Herraiz T; González D; Ancín-Azpilicueta C; Arán VJ; Guillén H
Food Chem Toxicol; 2010 Mar; 48(3):839-45. PubMed ID: 20036304
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationship study of beta-carboline derivatives as haspin kinase inhibitors.
Cuny GD; Ulyanova NP; Patnaik D; Liu JF; Lin X; Auerbach K; Ray SS; Xian J; Glicksman MA; Stein RL; Higgins JM
Bioorg Med Chem Lett; 2012 Mar; 22(5):2015-9. PubMed ID: 22335895
[TBL] [Abstract][Full Text] [Related]
19. β-carboline compounds, including harmine, inhibit DYRK1A and tau phosphorylation at multiple Alzheimer's disease-related sites.
Frost D; Meechoovet B; Wang T; Gately S; Giorgetti M; Shcherbakova I; Dunckley T
PLoS One; 2011 May; 6(5):e19264. PubMed ID: 21573099
[TBL] [Abstract][Full Text] [Related]
20. DYRK1A phosphorylates caspase 9 at an inhibitory site and is potently inhibited in human cells by harmine.
Seifert A; Allan LA; Clarke PR
FEBS J; 2008 Dec; 275(24):6268-80. PubMed ID: 19016842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
